Progress for a Cure for Herpes Continues

person standing on hand rails with arms wide open facing the mountains and clouds

Herpes Clinical Pipeline

AiCuris Non-Confidential Slide Deck May 2023: AiCuris planning for commercial launch of Priteliver 2025. Launch prep for Priteliver is ongoing.

Innovative Molecules advances IM-250: The clinical trial center in Heidelberg, Germany has Phase 2 clinical trials are scheduled for 2024. The clinical phase 1 study investigates the safety, tolerability, and pharmacokinetics of a medication in development (IM-250) against infections with herpes simplex viruses in healthy test subjects. Participants: Healthy men and non-pregnant women aged 18-50 years.

Thyreos Inc. Receives NIH NIAID $1.6 Million Grant For Preclinical Development of R2® Herpes Simplex Type 2 Vaccine

EG 427 announces issuance of the first 2 patents for its HSV-based gene therapy treatment

Herpes Cure Advocacy News

Want to join the advocates volunteer task force? Join this information session to learn more. Interested volunteers can apply here.


May 17th 6pm EST

What we’re reading…

Tired of ‘dead end’ approach, herpes patients mobilize to demand government action

Don’t ignore potential microbial causes of Alzheimer’s and other chronic diseases, researchers say

Chronic viral coinfections differentially affect the likelihood of developing long COVID

I Thought I Had A Headache. It Turned Out To Be Herpes (HSV-1) — In My Brain.

Want to support Public Awareness for Herpes cure, treatment and prevention?


Fundraiser for a public awareness campaign for the cure, treatment and prevention of herpes simplex virus types 1 and 2.


Make a one-time donation

Make a monthly donation

Make a yearly donation

Choose an amount


Or enter a custom amount

Your contribution is appreciated.

Your contribution is appreciated.

Your contribution is appreciated.

DonateDonate monthlyDonate yearly

Want the latest news on herpes cure, treatment and prevention?
Sign up for emails to make sure you never miss a thing.

Success! You're on the list.

Leave a Reply